Once considered an especially risky area of investment, the field of gene therapy increasingly is seen now as an attractive target for venture firms. The newest company to receive investors’ blessing is GenSight Biologics, a Paris-based startup that’s landed €32 million ($41.4 million) in Series A funding to study a pair of therapies for orphan ophthalmological disorders.
GenSight said April 8 that it had attracted capital from four firms: Novartis Venture Fund, Abingworth, Versant Ventures and Index Ventures
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?